|
COR Therapeutics, Inc. Resets Guidance for Third Quarter and Year-End 2001 SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Oct. 3, 2001--COR Therapeutics, Inc. announced today that third quarter sales of INTEGRILIN® (eptifibatide) Injection to wholesalers in the United States will be lower than previously anticipated. The Company said it expects U.S. sales to wholesalers to be approximately $53 million and worldwide sales to be approximately $59 million for the third quarter of 2001, primarily due to less than anticipated demand in September. The Company provided new earnings per share guidance for the third quarter of $0.01. For 2001, COR indicated that its new guidance for worldwide sales of INTEGRILIN is $240 to $250 million, and that earnings per share are expected to be $0.11 to $0.13, excluding a possible $10 million milestone payment related to European regulatory approval in angioplasty. The new earnings per share estimates for the quarter and year-end also reflect lower interest income on investments. COR said that U.S. hospital-based sales for July and August, according to third-party data, were in line with expectations. The Company also noted that in a growing market, patient share for INTEGRILIN increased to over 51 percent in August, the highest ever reported by COR. |
|
| aus der Diskussion: | Cor Therapeutics - was ist da los? |
| Autor (Datum des Eintrages): | puhvogel (04.10.01 09:21:15) |
| Beitrag: | 3 von 3 (ID:4559456) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |